Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies announced it has received full regulatory clearance from France's ANSM to conduct the PARADIGM Trial for its DurAVR® Transcatheter Heart Valve. The prospective randomized controlled trial will enroll approximately 1,000 patients to evaluate the safety and effectiveness of DurAVR® compared to commercially available TAVR devices, with patient recruitment now commencing at leading French centers.